Cargando…
Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial
OBJECTIVE: To determine the occurrence of extremely low HDL cholesterol (HDL-C) among participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial and to examine the relationship of this finding with treatment with fenofibrate and thiazolidinedione (TZD). RESEARCH DESIG...
Autores principales: | Linz, Peter E., Lovato, Laura C., Byington, Robert P., O’Connor, Patrick J., Leiter, Lawrence A., Weiss, Daniel, Force, Rex W., Crouse, John R., Ismail-Beigi, Faramarz, Simmons, Debra L., Papademetriou, Vasilios, Ginsberg, Henry N., Elam, Marshall B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931389/ https://www.ncbi.nlm.nih.gov/pubmed/24296848 http://dx.doi.org/10.2337/dc13-0790 |
Ejemplares similares
-
Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial
por: Miller, Michael E., et al.
Publicado: (2014) -
Hemodynamic Effects of Fenofibrate and Coenzyme Q(10) in Type 2 Diabetic Subjects With Left Ventricular Diastolic Dysfunction
por: Chew, Gerard T., et al.
Publicado: (2008) -
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
por: Farnier, Michel, et al.
Publicado: (2011) -
Type 2 Diabetes: Uses of thiazolidinediones and insulin
por: T. Bloomgarden, Zachary
Publicado: (2011) -
Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants
por: Mychaleckyj, Josyf C., et al.
Publicado: (2012)